Emma Yasinski

I am a freelance science and medical journalist, fascinated by how the scientific process leads to incredible discoveries, but also can lead to publication bias leaning toward positive findings and minimizing negatives. With a bachelor’s degree in neuroscience from Lafayette College and a Master’s in Science and Medical Journalism from Boston University, I’ve written about clinical trial transparency, organ donation, and basic molecular biology for publications like The Scientist, The Atlantic, Undark.org, Kaiser Health News, and more. At MedShadow, I research and write about the sometimes unexpected ways that medicines can affect us, and what we can do if and when it does.

When the first COVID-19 vaccination was authorized back in December  2020, millions of eligible people lined up at vaccination sites, sometimes for hours, waiting for protection from the disease. Age was one of the main factors, with the country’s oldest residents up first. Week after week, the age for eligibility lowered until it reached 16 for Moderna’s shot and 18 for Pfizer’s. Before, children under the age of either 16 (for Moderna) or 18 (for Pfizer) could be vaccinated, the shots needed to undergo additional testing to evaluate the appropriate doses, side effects and efficacy in younger individuals. For children…

Read More

Two recently authorized antiviral drugs designed to protect against the most severe outcomes of COVID-19 may be game-changers during the ongoing pandemic. Those benefits may come at a cost, however. It’s crucial that you and your healthcare providers understand these drugs’ potential side effects, so you use them as safely as possible. “Obviously, if you’ve got a serious case of COVID, you need to be treated,” despite the risk of side effects says Katherine Seley-Radtke, PhD, professor of chemistry and biochemistry at the University of Maryland, Baltimore County. How Effective Are They? Both drugs, Lagevrio (molnupiravir) and Paxlovid (nirmatrelvir and…

Read More